A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...
Main Authors: | Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, Ashok K. Shenoy, Priyanka Kamath |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/11/1365 |
Similar Items
-
Secukinumab
by: Nilgün Atakan
Published: (2022-04-01) -
On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
by: Pim Sermsaksasithorn, et al.
Published: (2022-10-01) -
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01) -
Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
by: T. V. Korotaeva, et al.
Published: (2017-04-01) -
Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
by: Tommaso Lupia, et al.
Published: (2022-10-01)